AIkido Pharma Executes Artificial Intelligence and Machine Learning Research Agreement with Cogia Biotech LTD

Agreement to Advance Genetic Marker Research for Pancreatic Cancer” data-reactid=”12″>Agreement to Advance Genetic Marker Research for Pancreatic Cancer

NEW YORK, May 6, 2020 /PRNewswire/ – AIkido Pharma Inc. (Nasdaq: AIKI) today announced execution of an Artificial Intelligence (AI), and Machine Learning (ML) research agreement with Cogia Biotech LTD (“Cogia”) (www.cogia.de) to accelerate the Company’s pancreatic cancer genetic marker research.  Cogia is a Big-data, AI, and ML software company committed to using powerful AI engines and algorithms to develop compelling outcomes in drug development.  Cogia provides state-of-the-art digital information and discovery tools to subject-matter experts and scientists working in genetics and cancer research, to advance drug development.  Cogia’s existing clients include many international companies, including international pharmaceutical companies.” data-reactid=”13″>NEW YORK, May 6, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) today announced execution of an Artificial Intelligence (AI), and Machine Learning (ML) research agreement with Cogia Biotech LTD (“Cogia”) (www.cogia.de) to accelerate the Company’s pancreatic cancer genetic marker research.  Cogia is a Big-data, AI, and ML software company committed to using powerful AI engines and algorithms to develop compelling outcomes in drug development.  Cogia provides state-of-the-art digital information and discovery tools to subject-matter experts and scientists working in genetics and cancer research, to advance drug development.  Cogia’s existing clients include many international companies, including international pharmaceutical companies.

More